| ALS genetics, mechanisms, and therapeutics: where are we now? R Mejzini, LL Flynn, IL Pitout, S Fletcher, SD Wilton, PA Akkari Frontiers in neuroscience 13, 497022, 2019 | 658 | 2019 |
| The effect of electromagnetic radiation in the mobile phone range on the behaviour of the rat WMU Daniels, IL Pitout, TJO Afullo, MV Mabandla Metabolic brain disease 24, 629-641, 2009 | 95 | 2009 |
| ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci 13: 1310 R Mejzini, LL Flynn, IL Pitout, S Fletcher, SD Wilton, PA Akkari | 24 | 2019 |
| Antisense oligonucleotide-mediated terminal intron retention of the SMN2 transcript LL Flynn, C Mitrpant, IL Pitout, S Fletcher, SD Wilton Molecular Therapy-Nucleic Acids 11, 91-102, 2018 | 21 | 2018 |
| Systematic approach to developing splice modulating antisense oligonucleotides MT Aung-Htut, CS McIntosh, KA Ham, IL Pitout, LL Flynn, K Greer, ... International journal of molecular sciences 20 (20), 5030, 2019 | 19 | 2019 |
| Antisense-mediated splice intervention to treat human disease: The odyssey continues I Pitout, LL Flynn, SD Wilton, S Fletcher F1000Research 8, 2019 | 17 | 2019 |
| ALS genetics, mechanisms, and therapeutics: Where are we now? Front Neurosci. 2019; 13: 1310 R Mejzini, LL Flynn, IL Pitout, S Fletcher, SD Wilton, PA Akkari Přejít k původnímu zdroji... Přejít na PubMed, 2019 | 12 | 2019 |
| Association of a structural variant within the SQSTM1 gene with amyotrophic lateral sclerosis J Pytte, RS Anderton, LL Flynn, F Theunissen, L Jiang, I Pitout, I James, ... Neurology: Genetics 6 (2), e406, 2020 | 10 | 2020 |
| DNAzymes: expanding the potential of nucleic acid therapeutics LM Larcher, IL Pitout, NP Keegan, RN Veedu, S Fletcher nucleic acid therapeutics 33 (3), 178-192, 2023 | 8 | 2023 |
| Single stranded fully modified-phosphorothioate oligonucleotides can induce structured nuclear inclusions, alter nuclear protein localization and disturb the transcriptome in vitro LL Flynn, R Li, IL Pitout, MT Aung-Htut, LM Larcher, JAL Cooper, KL Greer, ... Frontiers in Genetics 13, 791416, 2022 | 8 | 2022 |
| Targeted SMN Exon Skipping: A Useful Control to Assess In Vitro and In Vivo Splice-Switching Studies LL Flynn, C Mitrpant, A Adams, IL Pitout, A Stirnweiss, S Fletcher, ... Biomedicines 9 (5), 552, 2021 | 8 | 2021 |
| Interaction of modified oligonucleotides with nuclear proteins, formation of novel nuclear structures and sequence-independent effects on RNA processing LL Flynn, R Li, MT Aung-Htut, IL Pitout, JAL Cooper, A Hubbard, L Griffiths, ... BioRxiv, 446773, 2018 | 8 | 2018 |
| Characterising splicing defects of ABCA4 variants within exons 13–50 in patient-derived fibroblasts D Huang, JA Thompson, SC Chen, A Adams, I Pitout, A Lima, D Zhang, ... Experimental Eye Research 225, 109276, 2022 | 4 | 2022 |
| Modulation of CNOT3 expression using antisense oligomers to treat retinitis pigmentosa 11 J Grainok, I Pitout, S Wilton, FK Chen, C Mitrpant, S Fletcher Investigative Ophthalmology & Visual Science 62 (8), 1181-1181, 2021 | 2 | 2021 |
| Modulation of modifiers of pre-mRNA splicing: a therapeutic strategy for amenable inherited diseases I Pitout Murdoch University, 2018 | 1 | 2018 |
| A Precision Therapy Approach for Retinitis Pigmentosa 11 Using Splice-Switching Antisense Oligonucleotides to Restore the Open Reading Frame of PRPF31 J Grainok, IL Pitout, FK Chen, S McLenachan, RC Heath Jeffery, ... International journal of molecular sciences 25 (6), 3391, 2024 | | 2024 |
| Treatment of optic atrophy F Chen, I Pitout, J Grainok, S Utama, K Rice US Patent App. 18/026,388, 2023 | | 2023 |
| Novel Retinitis Pigmentosa Treatment S Fletcher, I Pitout, J Grainok, SD Wilton, FK Chen US Patent App. 17/614,495, 2022 | | 2022 |
| the odyssey continues [version 1; peer review: 3 approved] I Pitout, LL Flynn, SD Wilton, S Fletcher | | 2019 |
| A spanner in the works of human transformer 2 β1 autoregulation may reduce the severity of spinal muscular atrophy I Pitout, S Fletcher, S Etherington, S Wilton The Journal of Gene Medicine 17 (8-9), 173-217, 2015 | | 2015 |
